Human FREE soluble RANKL ELISA

Catalog number: BI-20462
Brand: Biomedica
Packing: 96 tests
Price: On Request
Expected delivery time: 7 days
Quantity:

Product specifications for - Human FREE soluble RANKL ELISA

Overview: 
Product group: Assays
Category: ELISA / EIA
Application note: ELISA
Reactivity note: human
Properties: 
Molecular weight: 20 kDa
Assay Sensitivity: 0.01 pmol/l (= 0.2 pg/ml)
Assay Specificity: free soluble RANKL (receptor activator of nuclear factor kappa B ligand)
Assay Precision: intra-assay: 4%, inter-assay: 3%
Assay Sample Type: Serum, heparin plasma
Assay Time: 2 h / overnight (cool +4°C) / 1 h / 30 min
Assay Detection Range: 0.0625-2 pmol/l
Datasheet: Datasheet
  Research Use Only
UNSPSC: 41116133
Scientific information: 
Scientific info: Product Characteristics: The Biomedica human free, soluble, uncomplexed RANKL (TNFSF11) high sensitvity Sandwich ELISA kit is intended for the quantitative measurement of sRANKL levels in serum and heparin plama samples. The free sRANKL ELISA is highly recognised with +250 publications to date, CE certified and approved for in-vitro diagnostic use in the EU.Target information: RANKL, the receptor activator of nuclear factor kappa B ligand, a member of the tumor necrosis factor (TNF) family, is the main stimulatory factor for the formation of mature osteoclasts and is essential for their survival. RANKL activates its specific receptor RANK, located on osteoclasts and dendritic cells. RANKL and its specific receptor RANK are not only key regulators of bone remodeling but also play an essential role in immunobiology, e.g. lymph node formation, establishment of the thymic microenviroment, mammary gland development during pregnancy, bone metastasis in cancer and sex-hormone, progestin-driven breast cancer, thermoregulation, and finally in the development of type 2 diabetes mellitus.
Gene ID: 21943
Swiss prot ID: O35235
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: BI-20462; Biomedica Gruppe; CD254; HRANKL; ODF; OPGL; OPTB2; RANK; TNFSF11; TNLG6B; TRANCE; WNT
Bruno D et al., “Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study.” Front Med (Lausanne). (2021); 25; 8:613889. Read more
Wunderle M et al., “RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women.” Sci Rep. (2020); 20;10(1):5171. Read more
Rachner TD et al., „Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.” Clin Cancer Res. (2019); 15;25(4):1369-1378. Read more
All Citations Read more